Cancer therapies sometimes involve drugs that mediate the breakdown of specific intracellular proteins that participate in cancer formation and proliferation. Proteolysis-targeting chimeras or PROTACs ...
NEW HAVEN, Conn., June 21, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today ...
I tested the Streamlights PROTAC HL® 4 HIGH LUMEN TACTICAL LIGHT, a dual power hand torch that throws can throw a beam out to 346 meters. The PROTAC HL® 4 is 8.63 inches long and weighs 1.1 lbs. It is ...
Proteolysis Targeting Chimeras (PROTACs) are a novel approach for degrading target proteins. Recently, a new split-and-mix PROTAC (SM-PROTAC) system based on liposome self-assembly, known as ...
Streamlight ® Inc. announced it has expanded its ProTac ® family of tactical lights to include enhanced versions of two of its models. The new lights, the ProTac ® HL-X and ProTac ® 2L-X, feature ...
A promising strategy to reduce the impact of viral infectious diseases, such as influenza, is the use of attenuated, live viruses as vaccines. However, the usefulness of traditional live-attenuated ...
Proteolytic targeting chimera (PROTAC) is a new type of drug design technology that works by inducing the degradation of target proteins. Unlike conventional small molecules that typically inhibit ...
– Preclinical data presented at the Biennial International LRRK2 Meeting highlighted the promise of PROTAC®-induced leucine-rich repeat kinase 2 (LRRK2) degradation as a potential treatment for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback